

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a | Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection MSA collection is from EVcouplings (v2) server: <http://v2.evcouplings.org>

Data analysis Open source code: pytorch (1.10.0), scikit-learn (0.23.1), xgboost (1.5.0), scipy (1.4.1), biopython (1.79), numpy (1.19.5), h5py (2.10.0), hyperopt (0.2.2), pandas (1.1.2), pickle (4.0), tqdm (4.32.1), gudhi (3.3.0), DeepSequence (Jul 2018), theano (1.0.5), esm (0.3.1), tensorflow (1.13.0 & 2.2.0), VMD (1.9.4), scipy (1.4.1), HERMES (1.0), TAPE (Aug, 2021; <https://github.com/songlab-cal/tape-neurips2019>), UniRep (Mar, 2020)  
Non-open source package: jackal (<http://honig.c2b2.columbia.edu/jackal>)  
The custom code for data analysis is available at <https://github.com/WeilabMSU/TopFit>

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

There are 34 DMS datasets with experimentally measured fitness used in this work including: 32 DeepSequence datasets [8], avGFP dataset [41], and GB1 dataset [42]. The original data sources of the 32 DeepSequence datasets are provided in Supplementary Data 1 and Supplementary Note 7. Structure data were obtained from PDB database [22] and AlphaFold [38], and the specific entry ID was provided in Supplementary Data 1.

The data analyzed and generated in this work, including sequence-to-fitness datasets, optimized structure data, multiple sequence alignments, fine-tune parameters for eUniRep models, predictions from evolutionary scores for individual mutations, and sequence- and structure- based embeddings are available at <https://github.com/WeilabMSU/TopFit> [65] and our lab server <https://weilab.math.msu.edu/Downloads/TopFit/>.

Source data for Figures 3, 4, 5, and Extended Data Figures 1, 3, 5, 6, 7, 8, 9, 10 is available with this manuscript. Source data for Extended Data Figures 2, 4 is available in Supplementary Data 2.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	<input type="text" value="N/A"/>
Population characteristics	<input type="text" value="N/A"/>
Recruitment	<input type="text" value="N/A"/>
Ethics oversight	<input type="text" value="N/A"/>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<input type="text" value="The size of data size is based on the available data from literature cited."/>
Data exclusions	<input type="text" value="Following the convention in DeepSequence, we exclude sequences with mutations at positions that have more than 30% gaps in MSAs. In addition, we exclude wildtype sequence in evaluating data."/>
Replication	<input type="text" value="For each evaluation, we repeat the evaluation for 20 times with different random seeds for fixed training data size: 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240, and 10 times for 80/20 train/test split and 5-fold cross validations. All replications were successful."/>
Randomization	<input type="text" value="For each evaluation, we randomly pick 20% of data for testing set. The remaining 80% data is used for training data selection. For 80/20 train/test split, all 80% data is used for training set. For other cases with fixed sizes (N) of training set, we randomly sample N data within these 80% data as training set for N=24, 48, ..., 240. All samples are allocated randomly."/>
Blinding	<input type="text" value="We are blinded to group allocation during data collection and analysis."/>

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

## Methods

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging